Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 9—September 2024
CME ACTIVITY - Research

Mortality Rate and Cause of Death in Adults with Extrapulmonary Nontuberculous Mycobacteria Infection, Denmark

On This Page
CME Introduction
Methods
Results
Discussion
CME Follow Up
Cite This Article
Figures
Figure
Tables
Table 1
Table 2
Table 3
Table 4
Downloads
Article
Appendix
RIS [TXT - 2 KB]
Article Metrics
Metric Details
Related Articles
Mosquitoes and Buruli Ulcer, Australia
Nontuberculous Mycobacteria, Denmark, 1991–2022
Costs of NTM Pulmonary Disease, South Korea
More articles on Tuberculosis
Author affiliations: University of Southern Denmark, Odense, Denmark (A.A. Pedersen, A. Løkke, I.K. Holden, O. Hilberg, I.S. Johansen); Lillebaelt Hospital, Vejle, Denmark (A.A. Pedersen, A. Løkke, R. Ibsen, O. Hilberg); Mycobacterial Centre for Research Southern Denmark, Odense (A.A. Pedersen, I.K. Holden, O. Hilberg, I.S. Johansen); Odense University Hospital, Odense, Denmark (A.A. Pedersen, I.K. Holden, I.S. Johansen); Aarhus University Hospital, Aarhus, Denmark (V.N. Dahl, A. Fløe)

Cite This Article

Introduction

CME Logo

Medscape CME ACTIVITY

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at https://www.medscape.org/qna/processor/72395?showStandAlone=true&src=prt_jcme_eid_mscpedu; and (4) view/print certificate.

NOTE: It is Medscape's policy to avoid the use of Brand names in accredited activities. However, in an effort to be as clear as possible, trade names are used in this activity to distinguish between the mixtures and different tests. It is not meant to promote any particular product.

Release date: August 21, 2024; Expiration date: August 21, 2025
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Distinguish differences in mortality rates among adults with extrapulmonary nontuberculous mycobacterial (E-NTM) disease and control participants

  • Analyze causes of death associated with E-NTM vs controls participants

  • Assess the demographic data of mortality outcomes among adults with E-NTM and control participants

CME Editor

Jill Russell, BA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Jill Russell, BA, has no relevant financial relationships.

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. Disclosure: Charles P. Vega, MD, has the following relevant financial relationships: served as consultant or advisor for Boehringer Ingelheim; GlaxoSmithKline.

Authors

Andreas A. Pedersen, MD; Victor N. Dahl, MD; Anders Løkke, MD, DMSc; Inge K. Holden, MD, MPH, PhD; Andreas Fløe, MD, PhD; Rikke Ibsen, MSc; Ole Hilberg MD, DMSc; Isik S. Johansen MD, DMSc.

Top

Abstract

Evidence on mortality rates and causes of death associated with extrapulmonary nontuberculous mycobacteria (NTM) infection is limited. This nationwide register-based study in Denmark used diagnostic codes to match adult patients with extrapulmonary NTM infection 1:4 to controls. During 2000–2017, we identified 485 patients, who had significantly more comorbidities than controls. The 5-year mortality rate for patients was 26.8% (95% CI 23.1%–31.0%) and for controls, 10.9% (95% CI 9.6%–12.4%). The median age at death was 76 (interquartile range 63–85) years for patients and 84 (interquartile range 73–90) years for controls. The adjusted hazard rate of death for patients was 1.34 (95% CI 1.10–1.63; p = 0.004). Patients and controls mainly died of cardiovascular disease and solid malignant neoplasms. Hematologic malignancies and HIV were more frequently causes of death in patients. Mortality rates are substantial among patients with extrapulmonary NTM infection, predominantly caused by underlying conditions.

Extrapulmonary nontuberculous mycobacteria (NTM) infection potentially affects any organ; lymph nodes, skin, and soft tissue are the most commonly affected (1,2). The severity of disease varies considerably from uncomplicated lymphadenitis with favorable prognosis among children to disseminated disease in immunocompromised patients (3–5). Still, a substantial knowledge gap remains regarding outcomes of extrapulmonary NTM disease (6).

Historically associated with HIV and AIDS, incidence of extrapulmonary NTM infection has been increasing and represents a growing healthcare challenge (1–3,7). This increase has been attributed to several factors, such as the intensified use of immunosuppressants, increased life expectancy, and increased awareness of the disease (1,3,8,9). Furthermore, extrapulmonary NTM has been implicated in iatrogenic infections and healthcare-related outbreaks (10–13). In addition, the discontinuation of the bacillus Calmette-Guérin (BCG) vaccine in areas with low tuberculosis incidence might have contributed to this increase, possibly because of reduced nonspecific immune protection previously provided by the vaccine (14)

Studies on extrapulmonary NTM–related deaths are scarce, and reported mortality rates vary widely. In a US cohort of 365 NTM infections, the mortality rate for extrapulmonary NTM was 2% and for disseminated NTM disease was 50% (15). In contrast, another US study of 831 extrapulmonary NTM patients from 2009–2014 reported an overall crude mortality rate of 5% (11% disseminated disease and 2% skin and soft tissue infections) (16). In patients with hematologic cancers, 30-day mortality has been reported at 15% in NTM-infected persons, compared with only 2% in noninfected persons (17).

In summary, extrapulmonary NTM represents a highly heterogeneous disease entity in terms of clinical manifestation and host factors, and knowledge of its associated mortality rates and causes of death among persons with extrapulmonary NTM disease is limited. To address this knowledge gap, we investigated mortality rates associated with diagnosis of extrapulmonary NTM infection and describe the causes of death.

Methods

Study Design

This study was a nationwide retrospective register-based cohort study from Denmark. The healthcare system is based on tax-funded universal healthcare. Different types of registers can be linked by using a unique 10-digit personal identification number issued to all citizens (18).

Data Sources and Measurement

The Danish Register of Causes of Death contains data on time, place, and cause of death using the International Classification of Diseases, 10th Revision (ICD-10), for all deaths occurring in Denmark (19). We identified all patients with extrapulmonary NTM infection using International Classification of Diseases, 8th Revision (ICD-8), and ICD-10 diagnostic codes from the National Patient Register. The register contains the ICD-8 and ICD-10 diagnostic codes and procedural codes on all inpatients from 1977 and all outpatients since 1995 (20). To evaluate the effects of baseline comorbidities on mortality, we calculated a Charlson Comorbidity Index (CCI) as described by Quan et al. (21) using ICD-10 codes from the National Patient Register.

Study Subjects

We included patients >18 years of age with a first-time extrapulmonary NTM disease ICD-10 code (A31.1, A31.8, or A31.9) during 2000–2017. The date of the first registered extrapulmonary NTM code was considered the index date. For persons without an extrapulmonary NTM–specific ICD-10 code (A31.1), we used procedural codes for specific examinations and treatments to differentiate between extrapulmonary NTM and other NTM disease manifestations in windows of 1 year on either side of the index date (Appendix Table). Patients and controls were censored from the study at death, migration, or end of data. We matched patients with extrapulmonary NTM disease to controls at a ratio of 1:4 at index. Controls were randomly selected from the total population of Denmark and matched by birth year, sex, marital status, and municipality of residence. The controls entered the study at the same date as the case-patient to whom they were matched. We excluded persons with an ICD-8 or ICD-10 code of A31 from the possible control population to ensure a nonbiased representative sample.

Statistical Analysis and Variables

We present absolute numbers and percentages or medians with interquartile ranges (IQRs) as appropriate. We evaluated differences between groups using the χ2 test and median age differences using the Wilcoxon-Mann-Whitney nonparametric test. Because of legislation in Denmark, descriptive variables with <3 observations were not reported to ensure patient privacy. We evaluated mortality rates using a cumulative mortality plot and tested differences using a log-rank test. We used the Cox proportional hazards model to estimate unadjusted hazard ratios (HRs) of death and adjusted for CCI (21). Because HRs were not constant over time (nonproportional), we estimated annual and average HRs in the study period (22). To investigate the effects of HIV and AIDS on mortality, we performed a sensitivity analysis by excluding patients with HIV from the analyses. We post hoc categorized comorbidities into 3 groups (overall burden of comorbidities, break in barrier function, and impaired immunity) on the basis of existing knowledge of risk factors for NTM infection to investigate the association of comparable comorbidities and morbidity (9,10,12,23–25). We examined causes of death using the 21 World Health Organization ICD-10 classification groups for cases and controls and qualified them using detailed data on causes of death for the most common groups for extrapulmonary NTM compared with controls. We performed statistical analyses using Stata version 16.1 (StataCorp LLC, https://www.stata.com) and SAS version 9.4 TS Level 1M5 (SAS Institute Inc., https://www.sas.com). We applied a significance level of 0.05 for all tests.

Ethics Statement

Ethics approval is not required for register studies according to Danish law. The Region of Southern Denmark (jr. no. 22/10240) approved the study.

Results

Patient Demographics

For the period spanning 2000–2017, we identified 485 patients with extrapulmonary NTM disease. Their median age at index was 57 (IQR 41–73) years; 40.4% of patients were women and 59.6% men, and 49.6% were married or cohabiting (Table 1). The median follow-up duration was 5 (IQR 3–10) years for extrapulmonary NTM patients and 6 (IQR 3–11) years for controls. NTM diagnostic codes for cutaneous infection accounted for 29.7% (Mycobacterium marinum in 13.2%, M. ulcerans in 1%), whereas 70.3% were reported as other or not otherwise specified.

Mortality Rates

The median age at death from all causes was 76 (IQR 63–85) years for extrapulmonary NTM patients compared with 84 (IQR 73–90) years in controls. In total, 158 (32.6%) of 485 extrapulmonary NTM patients died during the study period. Extrapulmonary NTM patients had a significantly higher mortality rate than did matched controls (mortality HR 1.9, 95% CI 1.58–2.29; p<0.0001); the largest difference occurred in the first 3 years after diagnosis. The cumulative 1-year mortality rate for extrapulmonary NTM patients was 9.3% (95% CI 7.0%–12.2%), compared with 3.1% (95% CI 2.4%–4.0%) for controls. The cumulative 5-year mortality rate was 26.8% (95% CI 23.1%–31.0%) for extrapulmonary NTM patients and 10.9% (95% CI 9.6%–12.4%) for controls (Figure).

The increased mortality rate remained after adjusting for baseline CCI with an HR of 1.34 (95% CI 1.10–1.63; p<0.01). The effect was most pronounced in the first 3 years (Table 2). After 4 years of follow-up, the hazards of death did not differ between extrapulmonary NTM patients and controls. The hazards of death remained higher for extrapulmonary NTM patients even when excluding persons with HIV from the analysis (HR 1.4, 95% CI 1.2–1.7).

Causes of Death

Patients with extrapulmonary NTM disease died more frequently from infectious diseases (10.8%, 95% CI 6.4–16.7) than did controls (2.1%, 95% CI 0.1–4.2). Cardiovascular disease and solid malignant neoplasms were the 2 most common causes of death for extrapulmonary NTM patients and for controls (Table 3). Cardiovascular disease was the cause of death for 17.7% of extrapulmonary NTM patients and 24.0% of controls, whereas solid malignant neoplasms caused 13.9% of deaths for extrapulmonary NTM patients and 16.5% of deaths for controls. Deaths caused by hematologic malignancies were significantly more common among extrapulmonary NTM patients (7.6%, 95% CI 4.0%–12.9%) than among controls (3.5%, 95% CI 1.9%–5.9%; p<0.05). Other bacterial diseases, a grouping that potentially includes NTM disease, accounted for 5.7% (95% CI 2.6%–10.5%) of deaths but was not reported for controls.

Comorbidities
Overall Burden of Comorbidities

Persons with extrapulmonary NTM infection had higher CCI scores and an overall significantly higher burden of comorbidities than did controls (Table 1). In particular, the burden of cardiovascular diseases was significantly higher in extrapulmonary NTM patients at 38.8% (95% CI 34.4%–43.3%) than among controls at 19.3% (95% CI 17.6%–21.2%). The burden of chronic lower respiratory diseases was also significantly higher in extrapulmonary NTM patients at 6.2% (95% CI 4.2%–8.7%) than among controls at 2.5% (95% CI 1.9%–3.3%) (Table 4). Metabolic disorders, benign neoplasms, diseases of the male genitalia, and diseases of the gastrointestinal tract were also more common in extrapulmonary NTM patients.

Break in Barrier Function

Several comorbidities related to break in barrier function were more common in extrapulmonary NTM patients than in controls. One third of extrapulmonary NTM patients (29.3%, 95% CI 25.3%–33.6%) had injuries to the head and musculoskeletal system, compared with 17.1% (95% CI 15.4–18.8) of controls. Complications from surgical and medical care were more common in extrapulmonary NTM patients: 7.8% (95% CI 5.6%–10.6%) from surgical care and 2.5% (95% CI 1.9%–3.3%) from medical care. Extrapulmonary NTM patients also experienced higher rates of skin and soft tissue diseases (17.1%, 95% CI 13.9%–20.8%) and diseases of veins and lymphatic tissues (6.4%, 95% CI 4.4%–9.0%). Extrapulmonary NTM patients had a higher proportion of urinary system disease at 21.0% (95% CI 17.5%–24.9%); of those, 8.8% (95% CI 4.1%–16.1%) had been treated with BCG intravesically before diagnosis.

Impaired Immunity

Pneumonia and other bacterial diseases were significantly more common in extrapulmonary NTM patients at 21.2% (95% CI 17.7%–25.2%) than among controls at 2.9% (95% CI 2.2%–3.8%). The same discrepancy applied to diabetes mellitus (9.5%, 95% CI 7.0%–12.5%), HIV (2.5%, 95% CI 1.3%–4.3%), and hematologic malignancies (2.5%, 95% CI 1.3%–4.3%). Last, the proportion of inflammatory polyarthropathies was higher in extrapulmonary NTM patients (12.2%, 95% CI 9.4%–15.4%) than in controls (3.7% 95% CI 2.9%–4.6%) (Table 4).

Discussion

We present a comprehensive characterization of mortality rates among persons with extrapulmonary NTM infection and a unique description of causes of death in this nationwide register-based cohort study over an 18-year period. Patients with extrapulmonary NTM disease had higher all-cause mortality and died more often of hematologic malignancies and HIV than did controls.

Patients with extrapulmonary NTM infection had a higher mortality rate than controls in the first 3 years, and that difference persisted when controlling for comorbidities. Men and women with extrapulmonary NTM infection had similar all-cause mortality rates. The overall mortality rate was 32.6%, which is considerably higher than the rate of 4% reported in a recent Australia study of 73 patients with extrapulmonary NTM disease (10). That dissimilarity is likely because of differences in the 2 populations’ sample sizes, demographics, burden of comorbidities, and disease manifestations.

Previous studies have shown that mortality rates among patients with extrapulmonary NTM infection are lower than that associated with pulmonary NTM disease and that mortality varies by localization, patient population, and NTM species (26). Disseminated infections with M. chimaera from heater–cooler units have been associated with a case-fatality rate of 45.5% (12). Comparable high mortality rates have been reported in different extrapulmonary NTM studies on peritonitis in immunosuppressed persons, patients with central nervous system infection, and persons who have undergone renal or allogeneic stem cell transplant (21%–50%) (27–30).

Understanding the cause of death for persons with extrapulmonary NTM disease is essential to identify patients who could benefit from earlier intervention (31). In this study, extrapulmonary NTM patients most often died of an underlying comorbidity, and only 5.7% of deaths were attributable to other bacterial diseases, potentially including NTM disease. Deaths caused by hematologic malignancies and HIV were more common in persons with extrapulmonary infection, and those diseases are also considered risk factors for NTM disease (2,10). Still, when excluding persons with HIV from our analyses, the mortality rate remained higher among patients with extrapulmonary infection. We did not observe significant differences in the 2 most common causes of death for persons with extrapulmonary NTM disease and controls.

Persons with extrapulmonary NTM infection had a significantly higher burden of comorbidities than did controls. That finding was evident when investigating the CCI and common categories of comorbidities in the years before the diagnosis. The higher proportion of cardiovascular disease, metabolic disorders, and chronic lower respiratory disease in extrapulmonary NTM patients may indicate a higher degree of frailty, leading to an increased incidence of extrapulmonary NTM infection. Cardiovascular disease has previously been identified as a risk factor for pulmonary NTM disease but, to our knowledge, has not been identified as such for extrapulmonary infection (25).

Several comorbidities, which might provide a port of entry for mycobacteria because of compromised barrier function, were more common in patients with extrapulmonary NTM disease. Those patients experienced higher proportions of injuries; skin and subcutaneous tissue disease; and diseases of the veins, lymphatic vessels, and lymph nodes that all expose skin and soft tissues to risk for infection. Surgical and medical complications were also more common, indicating that extrapulmonary NTM infection can be seen as iatrogenic, which has been described consistently (10,11).

We observed a higher proportion of benign neoplasms before NTM disease was diagnosed. Invasive procedures in the diagnostic process or the neoplasms itself could lead to compromised barrier function. Neoplasms could also to some degree be misclassifications that are in fact granulomatous formation caused by NTM. Diseases of the urinary system and male genital organs were significantly more common in extrapulmonary NTM patients. Only a few of those patients (9/102) had intravesical BCG installation, which could have been a confounder, because BCG installations are known to cause BCGitis (32). NTM infections of the genitourinary tract are extremely rare and are unlikely to explain the large proportion of genitourinary diseases in our population (33). Disease in the genitourinary tract might indicate impaired mucosa barrier function or poor overall health, which increases the risk for extrapulmonary NTM. In addition, gastrointestinal diseases and symptoms were more prevalent in patients with extrapulmonary NTM infection, which could suggest compromised barrier function in the intestines. However, the extrapulmonary NTM disease could be localized to the gastrointestinal tract, as is the case with M. genavense (34).

Immunosuppression is strongly associated with extrapulmonary NTM (35,36). Immunosuppression in patients with any manifestation of NTM has been associated with an increased risk for death (HR 3.5 [95% CI 1.5–8.4]), but only 13 of 118 patients had an extrapulmonary NTM diagnosis (37). In our study, extrapulmonary NTM patients had a significantly higher proportion of hematological malignancies, which implies a higher risk for infection because of impaired immunity. Patients with extrapulmonary infection had higher proportions of anemia, HIV/AIDS, and diabetes mellitus, which are also associated with impaired immunity (2,25,38). Our study confirms an association with immunosuppression and HIV infection, which was also shown in an Australia study (10). Still, HIV generally seems to be rare in patients with NTM in our setting.

The higher proportion of inflammatory polyarthropathies in extrapulmonary NTM patients could be related to the use of immunosuppressants. Anti–tumor necrosis factor α treatment and corticosteroids are well-described risk factors for mycobacterial disease (9,25,39). A high mortality rate has been reported among patients treated with biological agents who have concomitant NTM infections (9).

The significantly higher proportion of extrapulmonary NTM patients with other bacterial diseases and pneumonia could be associated with an increased likelihood of immune dysfunction (40). Pneumonia is also a risk factor for pulmonary NTM (25). However, that finding could also be because of misdiagnoses and erroneous use of diagnostic codes.

This study was based on national registers, and the data entered in those registers imply an inherent risk for underreporting, overreporting, and misclassification. Treatment of extrapulmonary NTM disease is centralized in 6 hospitals in Denmark with specialized centers for mycobacterial diseases, and we are confident that the diagnoses have a high rate of accuracy. Previous validations of diagnostic codes in our registers have shown a high positive predictive value (41,42). The ICD-10 codes pertaining to extrapulmonary NTM manifestation and species are only specific for skin infections with M. marinum and M. ulcerans, and the registers used in this study do not contain data on microbiology or all relevant risk factors (e.g., type of immunosuppressants). This factor limited our ability to precisely describe the type, localization, and pathogenicity of NTM infections, including species. Nevertheless, the percentage of extrapulmonary NTM skin infections in our study (29.7%) is comparable to those in a US culture-based study (32%) (16). We assume that using ICD-10 codes for extrapulmonary NTM disease correlates well with clinically relevant disease compared with relying on microbiologic data alone. Furthermore, the inclusion of M. ulcerans patients could be debated, because M. ulcerans might not be considered as a separate disease entity, although it is genetically very similar to M. marinum (6,43,44).

Data on the causes of death are registered by the physician who verifies the death. However, those physicians might not be familiar with the patient’s entire medical history or with complex infections, making it difficult to differentiate between causes of death in this comorbid population. The low number of autopsies conducted in Denmark calls into question the validity of the death certificates; however, that issue appears to be common in other settings (31).

In conclusion, patients with extrapulmonary NTM infection have a significantly higher burden of comorbidities than do matched controls. The mortality rate remained higher for persons with extrapulmonary NTM infection than for matched controls after adjusting for a comorbidity severity index. In addition, patients with extrapulmonary NTM disease often die from underlying comorbidities, such as hematologic malignancies and HIV, not from extrapulmonary NTM disease.

Top

Acknowledgments

Data are not publicly available due to local legislative limitations.

This work was supported by The Region of Southern Denmark, A.P. Møller Foundation (to A.A.P.), Eva Merete Falck Crones Foundation (to A.A.P.), and Lillebaelt Hospital (to A.A.P.). The study funders had no role in study design, data collection, data analysis, data interpretation, or manuscript writing.

A.A.P., O.H., I.S.J., A.F., I.K.H., V.N.D., and A.L. designed the study. R.I. and A.A.P. performed the analysis. A.A.P. drafted the manuscript. All authors have critically reviewed and approved the final version of the manuscript.

Top

References

  1. Kiselinova  M, Naesens  L, Huis In ’t Veld  D, Boelens  J, Van Braeckel  E, Vande Weygaerde  Y, et al. Management challenges of extrapulmonary nontuberculous mycobacterial infection: a single-center case series and literature review. Pathogens. 2023;13:12. DOIPubMedGoogle Scholar
  2. Grigg  C, Jackson  KA, Barter  D, Czaja  CA, Johnston  H, Lynfield  R, et al. Epidemiology of pulmonary and extrapulmonary nontuberculous mycobacteria infections at 4 US emerging infections program sites: a 6-month pilot. Clin Infect Dis. 2023;77:629–37. DOIPubMedGoogle Scholar
  3. Bhanushali  J, Jadhav  U, Ghewade  B, Wagh  P. Unveiling the clinical diversity in nontuberculous mycobacteria (NTM) infections: a comprehensive review. Cureus. 2023;15:e48270. DOIPubMedGoogle Scholar
  4. Reuss  A, Drzymala  S, Hauer  B, von Kries  R, Haas  W. Treatment outcome in children with nontuberculous mycobacterial lymphadenitis: A retrospective follow-up study. Int J Mycobacteriol. 2017;6:76–82. DOIPubMedGoogle Scholar
  5. Jensen  FN, Nielsen  AB, Dungu  KHS, Poulsen  A, Schmidt  G, Hjuler  T, et al. Distinct clinical parameters were associated with shorter spontaneous resolution in children with non-tuberculous mycobacterial lymphadenitis. Acta Paediatr. 2024;apa.17104.
  6. Daley  CL, Iaccarino  JM, Lange  C, Cambau  E, Wallace  RJ Jr, Andrejak  C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71:e1–36. DOIPubMedGoogle Scholar
  7. Pedersen  AA, Løkke  A, Fløe  A, Ibsen  R, Johansen  IS, Hilberg  O. Nationwide increasing incidence of nontuberculous mycobacterial diseases among adults in Denmark—eighteen years of follow-up. Chest. 2024;•••:S0012-3692(24)00393-3; Epub ahead of print.PubMedGoogle Scholar
  8. Henkle  E, Winthrop  KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36:91–9. DOIPubMedGoogle Scholar
  9. Ashizawa  H, Takazono  T, Kawashiri  SY, Nakada  N, Ito  Y, Ashizawa  N, et al. Risk factor of non-tuberculous Mycobacterium infection in patients with rheumatoid arthritis and other autoimmune diseases receiving biologic agents: A multicenter retrospective study. Respir Investig. 2024;62:322–7. DOIPubMedGoogle Scholar
  10. Nohrenberg  M, Wright  A, Krause  V. Non-tuberculous mycobacterial skin and soft tissue infections in the Northern Territory, Australia, 1989-2021. Int J Infect Dis. 2023;135:125–31. DOIPubMedGoogle Scholar
  11. Malhotra  AM, Arias  M, Backx  M, Gadsby  J, Goodman  A, Gourlay  Y, et al. Extrapulmonary nontuberculous mycobacterial infections: a guide for the general physician. Clin Med (Lond). 2024;24:100016. DOIPubMedGoogle Scholar
  12. Wetzstein  N, Kohl  TA, Diricks  M, Mas-Peiro  S, Holubec  T, Kessel  J, et al. Clinical characteristics and outcome of Mycobacterium chimaera infections after cardiac surgery: systematic review and meta-analysis of 180 heater-cooler unit-associated cases. Clin Microbiol Infect. 2023;29:1008–14. DOIPubMedGoogle Scholar
  13. Buser  GL, Laidler  MR, Cassidy  PM, Moulton-Meissner  H, Beldavs  ZG, Cieslak  PR. Outbreak of nontuberculous mycobacteria joint prosthesis infections, Oregon, USA, 2010–2016. Emerg Infect Dis. 2019;25:849–55. DOIPubMedGoogle Scholar
  14. Shah  JA, Lindestam Arlehamn  CS, Horne  DJ, Sette  A, Hawn  TR. Nontuberculous mycobacteria and heterologous immunity to tuberculosis. J Infect Dis. 2019;220:1091–8. DOIPubMedGoogle Scholar
  15. Hannah  CE, Ford  BA, Chung  J, Ince  D, Wanat  KA. Characteristics of nontuberculous mycobacterial infections at a midwestern tertiary hospital: a retrospective study of 365 patients. Open Forum Infect Dis. 2020;7:ofaa173. DOIPubMedGoogle Scholar
  16. Ricotta  EE, Adjemian  J, Blakney  RA, Lai  YL, Kadri  SS, Prevots  DR. Extrapulmonary nontuberculous mycobacteria infections in hospitalized patients, United States, 2009–2014. Emerg Infect Dis. 2021;27:845–52. DOIPubMedGoogle Scholar
  17. Chen  CY, Sheng  WH, Lai  CC, Liao  CH, Huang  YT, Tsay  W, et al. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis. 2012;31:1059–66. DOIPubMedGoogle Scholar
  18. Schmidt  M, Pedersen  L, Sørensen  HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9. DOIPubMedGoogle Scholar
  19. Helweg-Larsen  K. The Danish register of causes of death. Scand J Public Health. 2011;39(Suppl):26–9. DOIPubMedGoogle Scholar
  20. Schmidt  M, Schmidt  SA, Sandegaard  JL, Ehrenstein  V, Pedersen  L, Sørensen  HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90. DOIPubMedGoogle Scholar
  21. Quan  H, Li  B, Couris  CM, Fushimi  K, Graham  P, Hider  P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–82. DOIPubMedGoogle Scholar
  22. Borucka  J. Extensions of Cox model for non-proportional hazards purpose. Ekonometria. 2014;3(45).
  23. Omori  K, Kitagawa  H, Yamaguchi  K, Sakamoto  S, Horimasu  Y, Masuda  T, et al. Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan. J Infect Chemother. 2023;29:875–81. DOIPubMedGoogle Scholar
  24. Hamed  KA, Tillotson  G. A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges. Expert Rev Respir Med. 2023;17:973–88. DOIPubMedGoogle Scholar
  25. Loebinger  MR, Quint  JK, van der Laan  R, Obradovic  M, Chawla  R, Kishore  A, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest. 2023;164:1115–24. DOIPubMedGoogle Scholar
  26. Mirsaeidi  M, Machado  RF, Garcia  JG, Schraufnagel  DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS One. 2014;9:e91879. DOIPubMedGoogle Scholar
  27. Baldolli  A, Daurel  C, Verdon  R, de La Blanchardière  A. High mortality in peritonitis due to Mycobacterium avium complex: retrospective study and systematic literature review. Infect Dis (Lond). 2019;51:81–90. DOIPubMedGoogle Scholar
  28. Cinicola  BL, Ottaviano  G, Hashim  IF, Zainudeen  ZT, Hamid  IJA, Elfeky  R. Prevalence and characteristics of non-tuberculous mycobacteria (NTM) infection in recipients of allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. J Clin Immunol. 2023;44:23. DOIPubMedGoogle Scholar
  29. Song  Y, Zhang  L, Yang  H, Liu  G, Huang  H, Wu  J, et al. Nontuberculous mycobacterium infection in renal transplant recipients: a systematic review. Infect Dis (Lond). 2018;50:409–16. DOIPubMedGoogle Scholar
  30. Meena  DS, Kumar  D, Meena  V, Bohra  GK, Tak  V, Garg  MK. Epidemiology, clinical presentation, and predictors of outcome in nontuberculous mycobacterial central nervous system infection: a systematic review. Trop Med Health. 2023;51:54. DOIPubMedGoogle Scholar
  31. Griffith  DE, Marras  TK. Nontuberculous mycobacterial disease epidemiology: you can see the stars and still not see the light. Clin Infect Dis. 2021;73:e327–9. DOIPubMedGoogle Scholar
  32. Larsen  ES, Nordholm  AC, Lillebaek  T, Holden  IK, Johansen  IS. The epidemiology of bacille Calmette-Guérin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019;124:910–6. DOIPubMedGoogle Scholar
  33. Huang  CT, Chen  CY, Chen  HY, Chou  CH, Ruan  SY, Lai  CC, et al. Genitourinary infections caused by nontuberculous mycobacteria at a university hospital in Taiwan, 1996-2008. Clin Microbiol Infect. 2010;16:1585–90. DOIPubMedGoogle Scholar
  34. Wetzstein  N, Kessel  J, Bingold  TM, Carney  J, Graf  C, Koch  BF, et al. High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis. J Infect. 2022;84:8–16. DOIPubMedGoogle Scholar
  35. Sexton  P, Harrison  AC. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J. 2008;31:1322–33. DOIPubMedGoogle Scholar
  36. Lake  MA, Ambrose  LR, Lipman  MCI, Lowe  DM. '“Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med. 2016;14:54. DOIPubMedGoogle Scholar
  37. Chai  J, Han  X, Mei  Q, Liu  T, Walline  JH, Xu  J, et al. Clinical characteristics and mortality of non-tuberculous mycobacterial infection in immunocompromised vs. immunocompetent hosts. Front Med (Lausanne). 2022;9:884446. DOIPubMedGoogle Scholar
  38. Oh  TK, Song  K-H, Song  I-A. History of anemia and long-term mortality due to infection: a cohort study with 12 years follow-up in South Korea. BMC Infect Dis. 2021;21:674. DOIPubMedGoogle Scholar
  39. Winthrop  KL, Baxter  R, Liu  L, Varley  CD, Curtis  JR, Baddley  JW, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42. DOIPubMedGoogle Scholar
  40. Chapel  H, Lucas  M, Lee  M, Bjorkander  J, Webster  D, Grimbacher  B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277–86. DOIPubMedGoogle Scholar
  41. Bølling-Ladegaard  E, Dreier  JW, Christensen  J. Identification of drug resistance in a validated cohort of incident epilepsy patients in the Danish National Patient Register. Epilepsia. 2023;64:2604–16. DOIPubMedGoogle Scholar
  42. Albaek Jacobsen  H, Jess  T, Larsen  L. Validity of inflammatory bowel disease diagnoses in the Danish National Patient Registry: a population-based study from the North Denmark Region. Clin Epidemiol. 2022;14:1099–109. DOIPubMedGoogle Scholar
  43. Guglielmetti  L, Mougari  F, Lopes  A, Raskine  L, Cambau  E. Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists’ point of view. Future Microbiol. 2015;10:1467–83. DOIPubMedGoogle Scholar
  44. Turenne  CY. Nontuberculous mycobacteria: Insights on taxonomy and evolution. Infect Genet Evol. 2019;72:159–68. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to https://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Mortality Rate and Cause of Death in Adults with Extrapulmonary Nontuberculous Mycobacteria Infection, Denmark
CME Questions

  • What was the rate of increased mortality associated with extrapulmonary nontuberculous mycobacterial (E-NTM) disease after adjustment for comorbidity in the current study?

    • 2% (no significant difference vs control participants)

    • 34%

    • 115%

    • 488%

  • Which of the following causes of death were more common in the control vs E-NTM disease cohorts in the current study?

    • Respiratory disease and cardiovascular disease

    • Hematologic malignancy and respiratory disease

    • Hematologic malignancy and solid malignant neoplasms

    • Cardiovascular disease and solid malignant neoplasms

  • Which of the following causes of death was most important in driving the difference between the E-NTM disease and control cohorts in the current study?

    • HIV

    • Hematologic malignancy

    • End-stage kidney disease

    • Respiratory disease

  • Which of the following statements regarding mortality in the E-NTM vs control cohorts in the current study is most accurate?

    • E-NTM disease was associated with a higher risk for death among women vs men

    • E-NTM disease was associated with a higher risk for death among men vs women

    • E-NTM disease was associated with a higher risk for death only among persons born outside Denmark

    • E-NTM disease was associated with its highest risk for death during the first 3 years of follow-up

Top

Cite This Article

DOI: 10.3201/eid3009.240475

Original Publication Date: August 21, 2024

Related Links

Table of Contents – Volume 30, Number 9—September 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Andreas Arnholdt Pedersen, Department of Medicine, Lillebaelt Hospital, Beriderbakken 4, 7100 Vejle, Denmark

Send To

10000 character(s) remaining.

Top

Page created: August 01, 2024
Page updated: August 21, 2024
Page reviewed: August 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external